Abgenix, Inc.

Antibody product maker files resale registration statement

Published in Lab Business Week, April 24th, 2005

Abgenix, Inc., (ABGX) has filed a resale registration statement on Form S-3 with the U.S. Securities and Exchange Commission covering its 1.75% Convertible Senior Notes due December 2011 and the common stock issuable upon conversion of the notes.

As previously announced, the notes were issued in a private placement in December 2004.

The company did not issue any new securities and will not receive any proceeds from the resale of securities under this registration statement.

The company's antibody development platform includes manufacturing capabilities that enable the rapid generation, selection and production of high affinity,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry